Skip to main navigation Skip to search Skip to main content

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

YOSEMITE and RHINE Investigators

Research output: Contribution to journal › Article › peer-review

416   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science